Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nicolás González-Vacarezza1, Eduardo Gehling Bertoldi2, Ana Deminco1

  • 1División Evaluación Sanitaria, Ministerio de Salud Pública, Montevideo, Uruguay.

Value in Health Regional Issues
|April 29, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Therapies for Heart Failure in Brazil: A Systematic Review.

Arquivos brasileiros de cardiologia·2026
Same author

May Measurement Month 2022: an analysis of blood pressure screening results from Paraguay.

European heart journal supplements : journal of the European Society of Cardiology·2025
Same author

Cost-Utility of Venoarterial Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock: A Brazilian Perspective Study.

Arquivos brasileiros de cardiologia·2024
Same author

Assessing the cost-effectiveness of capnography for end-tidal CO<sub>2</sub> monitoring during in-hospital cardiac arrest: A middle-income country perspective analysis.

American heart journal plus : cardiology research and practice·2024
Same author

May Measurement Month 2017-19: an analysis of blood pressure screening results from Paraguay<sup></sup>.

European heart journal supplements : journal of the European Society of Cardiology·2022
Same author

National Registry of Acute Coronary Syndrome in Paraguay (RENASCA-PY).

Archivos de cardiologia de Mexico·2022

Biologic drugs for psoriatic arthritis, including infliximab, adalimumab, and etanercept, are not cost-effective for Uruguay's National Health System. Lowering drug prices may improve cost-effectiveness outcomes.

Area of Science:

  • Pharmacoeconomics
  • Health Technology Assessment
  • Rheumatology

Context:

  • Psoriatic arthritis treatment in Uruguay.
  • Evaluating biologic drugs (adalimumab, etanercept, infliximab) for formulary inclusion.
  • First-line treatment failure in psoriatic arthritis patients.

Purpose:

  • To conduct a cost-utility analysis of anti-TNF biologics for psoriatic arthritis.
  • To inform evidence-based decisions for the National Formulary of Uruguay.
  • To compare the cost-effectiveness of infliximab, adalimumab, and etanercept against palliative care.

Summary:

  • A Markov model evaluated biologic treatments from the National Health System perspective over 40 years.
  • Infliximab had an ICER of $47,294; adalimumab and etanercept were dominated.
Keywords:
arthritiscost-effectivenesscost-utilitypsoriatic

Related Experiment Videos

  • Probabilistic sensitivity analysis indicated no biologic was cost-effective at the WTP threshold.

    • Impact:

    • Biologic treatments for psoriatic arthritis exceed Uruguay's WTP ceiling.
    • Intravenous administration of infliximab may create access inequities.
    • Reducing drug prices is recommended to improve cost-effectiveness for psoriatic arthritis management.